WALTHAM, Mass.--(BUSINESS WIRE)--May 31, 2012-- NeuroMetrix, Inc.
(Nasdaq: NURO), www.neurometrix.com, a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, reported today that it will exhibit and participate in the American Diabetes Association (ADA) 72nd Scientific Sessions. The ADA Scientific Sessions will be held on June 8-12 in Philadelphia at the Pennsylvania Convention Center.
NeuroMetrix will feature the NC-stat(R) DPNCheck(TM), a medical device providing a fast, accurate, and quantitative point-of-care test for the detection of systemic neuropathies, such as diabetic peripheral neuropathy (DPN). DPN affects over 50% of people with diabetes and can trigger foot ulcers that may require amputation, as well as severe and debilitating foot and lower leg pain known as painful diabetic neuropathy. Over 500 NC-stat DPNCheck devices have been shipped since the fourth quarter of 2011. Live demonstrations of NC-stat DPNCheck will be conducted at the NeuroMetrix booth.
The clinical benefits of sural nerve conduction measurement at the point-of-care include: -- Early detection of DPN, even in the absence of clinical symptoms and signs -- Help with confirmation or rule-out of DPN and quantification of severity -- Monitoring changes in DPN over time and in response to treatment The company will also introduce the SENSUS(TM) pain management device.
SENSUS is a transcutaneous electrical nerve stimulator uniquely designed to be used in managing chronic pain in the foot and lower leg, such as due to painful diabetic neuropathy. Several SENSUS devices will be on display at the NeuroMetrix booth to help physicians and other interested parties better understand how this novel device can benefit their diabetic patients suffering from painful diabetic neuropathy. SENSUS is the subject of a recent 510(k) premarket approval filing with the Food and Drug Administration (FDA) and is not currently available for commercial distribution.
Additional company activities will include presentation of a scientific poster titled "Reproducibility of a Rapid Point-of-Care Sural Nerve Conduction Test" by Dr. Kenneth J. Snow, NeuroMetrix Chief Medical Officer. This study demonstrates that NC-stat DPNCheck test results are highly reproducible thereby supporting use of the device in monitoring development and progression of DPN. The company will also conduct a meeting of its scientific advisory board consisting of international leaders in the detection, management, and treatment of the neurological complications of diabetes.
NeuroMetrix senior management including Dr. Shai N. Gozani, President and CEO, Thomas T. Higgins, Senior Vice President and CFO, and K.
Balachandran, Senior Vice President and COO will be attending the meeting. Attendees are encouraged to visit NeuroMetrix at booth #543.
About NeuroMetrix NeuroMetrix is an innovative medical device company that develops and markets home use and point-of-care devices, associated consumables, and support software for the treatment and management of diabetes and its complications. The company is focused on nerve related complications of diabetes, called diabetic neuropathies, which affect over 50% of people with diabetes. If left untreated, diabetic neuropathies trigger foot ulcers that may require amputation, cause disabling pain, and increase the risk of falling in the elderly. The annual cost of diabetic neuropathies has been estimated at $14 billion in the United States. The company's products are used by physicians and other clinicians, in retail health settings such as pharmacies, and by managed care organizations to optimize patient care and reduce healthcare costs. The company markets the NC-stat(R) DPNCheck(TM) device, which is a rapid, accurate, and quantitative point-of-care test for diabetic neuropathy. This product is used to detect diabetic neuropathy at an early stage and to guide treatment. The company is in late stage development of SENSUS(TM), a pain management device that will be used to treat painful diabetic neuropathy, a form of chronic intractable pain. Currently, painful diabetic neuropathy is treated pharmacologically, which is a $2 billion annual market. The company has additional therapeutic products in its pipeline. For more information, please visit http://www.neurometrix.com.
CONTACT: NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761 SVP and Chief Financial Officer email@example.com KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY MEDICAL DEVICES MENTAL HEALTH PHARMACEUTICAL OTHER HEALTH RESEARCH DIABETES SCIENCE SOURCE: NeuroMetrix, Inc.
Copyright Business Wire 2012 PUB: 05/31/2012 12:23 PM/DISC: 05/31/2012 12:23 PM http://www.businesswire.com/news/home/20120531006336/